Læknablaðið - 01.02.2014, Síða 18

82 LÆKNAblaðið 2014/100
Heimildir
1. Levin B, Lieberman DA, McFarland B, Smith RA, Brooks
D, Andrews KS, et al. Screening and surveillance for the
early detection of colorectal cancer and adenomatous
polyps, 2008: a joint guideline from the American Cancer
Society, the US Multi-Society Task Force on Colorectal
Cancer, and the American College of Radiology. CA
Cancer J Clin 2008; 58: 130-60.
2. Kuipers EJ, Rosch T, Bretthauer M. Colorectal cancer
screening--optimizing current strategies and new direc-
tions. Nat Rev Clin Oncol 2013; 10: 130-42.
3. Engholm G, Ferlay J, Christensen N, Johannesen TB,
Klint A, Kotlum JE, et al. NORDCAN: Cancer Incidence,
Mortality, Prevalence and Survival in the Nordic
Countries, Version 5.3 (25.04.2013). Association of the
Nordic Cancer Registries. Danish Cancer Society. ancr.
nu - október 2013.
4. Center MM, Jemal A, Ward E. International trends in
colorectal cancer incidence rates. Cancer Epidemiol
Biomarkers Prev 2009; 18: 1688-94.
5. Siegel RL, Jemal A, Ward EM. Increase in incidence of
colorectal cancer among young men and women in the
United States. Cancer Epidemiol Biomarkers Prev 2009;
18: 1695-8.
6. Snaebjornsson P, Jonasson L, Jonsson T, Moller PH,
Theodors A, Jonasson JG. Colon cancer in Iceland--a
nationwide comparative study on various pathology
parameters with respect to right and left tumor location
and patients age. Int J Cancer 2010; 127: 2645-53.
7. Siegel RL, Ward EM, Jemal A. Trends in colorectal cancer
incidence rates in the United States by tumor location and
stage, 1992-2008. Cancer Epidemiol Biomarkers Prev 2012;
21: 411-6.
8. Thorn M, Bergstrom R, Kressner U, Sparen P, Zack M,
Ekbom A. Trends in colorectal cancer incidence in Sweden
1959-93 by gender, localization, time period, and birth
cohort. Cancer Causes Control 1998; 9: 145-52.
9. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou
R, Altekruse SF, et al. SEER Cancer Statistics Review,
1975-2009 (Vintage 2009 Populations), National Cancer
Institute. Bethesda, MD, seer.cancer.gov/csr/1975_2009_
pops09/, based on November 2011 SEER data submission,
posted to the SEER web site, April 2012.
10. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012.
CA Cancer J Clin 2012; 62: 10-29.
11. Alexiusdottir KK, Moller PH, Snaebjornsson P, Jonasson
L, Olafsdottir EJ, Bjornsson ES, et al. Association of
symptoms of colon cancer patients with tumor location
and TNM tumor stage. Scand J Gastroenterol. 2012; 47:
795-801.
12. SEER Stat Fact Sheets: Colorectal Cancer (seer.cancer.gov/
statfacts/html/colorect.html). Vol. 2009.
13. Lynch HT, de la Chapelle A. Hereditary colorectal cancer.
N Engl J Med 2003; 348: 919-32.
14. Winawer SJ, Zauber AG, Gerdes H, O‘Brien MJ, Gottlieb
LS, Sternberg SS, et al. Risk of colorectal cancer in the
families of patients with adenomatous polyps. National
Polyp Study Workgroup. N Engl J Med 1996; 334: 82-7.
15. Atkin WS, Morson BC, Cuzick J. Long-term risk of colorec-
tal cancer after excision of rectosigmoid adenomas. N Engl
J Med 1992; 326: 658-62.
16. Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA
technical review on the diagnosis and management of
colorectal neoplasia in inflammatory bowel disease.
Gastroenterology 2010; 138: 746-74, 774 e741-744; quiz
e712-743.
17. Botteri E, Iodice S, Bagnardi V, Raimondi S, Lowenfels AB,
Maisonneuve P. Smoking and colorectal cancer: a meta-
analysis. JAMA 2008; 300: 2765-78.
18. Boyle T, Keegel T, Bull F, Heyworth J, Fritschi L. Physical
Activity and Risks of Proximal and Distal Colon Cancers:
A Systematic Review and Meta-analysis. J Natl Cancer Inst
2012; 104: 1548-61.
19. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW,
Mehta Z. Effect of daily aspirin on risk of cancer metas-
tasis: a study of incident cancers during randomised
controlled trials. Lancet 2012; 379: 1591-601.
20. Park Y, Leitzmann MF, Subar AF, Hollenbeck A, Schatzkin
A. Dairy food, calcium, and risk of cancer in the NIH-
AARP Diet and Health Study. Arch Intern Med 2009; 169:
391-401.
21. Park Y, Hunter DJ, Spiegelman D, Bergkvist L, Berrino F,
van den Brandt PA, et al. Dietary fiber intake and risk of
colorectal cancer: a pooled analysis of prospective cohort
studies. JAMA 2005; 294: 2849-57.
22. Koushik A, Hunter DJ, Spiegelman D, Beeson WL, van
den Brandt PA, Buring JE, et al. Fruits, vegetables, and
colon cancer risk in a pooled analysis of 14 cohort studies.
J Natl Cancer Inst 2007; 99: 1471-83.
23. Larsson SC, Wolk A. Meat consumption and risk of
colorectal cancer: a meta-analysis of prospective studies.
Int J Cancer 2006; 119: 2657-64.
24. Citarda F, Tomaselli G, Capocaccia R, Barcherini S, Crespi
M. Efficacy in standard clinical practice of colonoscopic
polypectomy in reducing colorectal cancer incidence. Gut
2001; 48: 812-5.
25. Winawer SJ, Zauber AG, O‘Brien MJ, Ho MN, Gottlieb
L, Sternberg SS, et al. Randomized comparison of
surveillance intervals after colonoscopic removal of newly
diagnosed adenomatous polyps. The National Polyp
Study Workgroup. N Engl J Med 1993; 328: 901-6.
26. Theodórs Á, Sigurðsson F, Jónsson JS, Cariglia N, Ólafsson
S, Stefánsson T. Skimun fyrir krabbameinum í ristli og
endaþarmi. Klínískar leiðbeiningar. Landlæknisembættið
2002. landlaeknir.is/gaedi-og-eftirlit/heilbrigdisstarfs-
folk/klininskar-leidbeiningar/leidbeiningar/item15089/
Ristilkrabbamein - febrúar 2013.
27. Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X,
Qian ZR, et al. Long-term colorectal-cancer incidence and
mortality after lower endoscopy. N Engl J Med 2013; 369:
1095-105.
28. Shaukat A, Mongin SJ, Geisser MS, Lederle FA, Bond JH,
Mandel JS, et al. Long-term mortality after screening for
colorectal cancer. N Engl J Med 2013; 369: 1106-14.
29. Quintero E, Castells A, Bujanda L, Cubiella J, Salas D,
Lanas A, et al. Colonoscopy versus fecal immunochemical
testing in colorectal-cancer screening. N Engl J Med 2012;
366: 697-706.
30. Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas
HJ, Evans GD, et al. Guidelines for colorectal cancer
screening and surveillance in moderate and high risk
groups (update from 2002). Gut 2010; 59: 666-89.
31. NCCN Clinical Practice Guidelines in Oncology: Colon
Cancer. Version 3.2013. 2012.
32. Nelson H, Petrelli N, Carlin A, Couture J, Fleshman J,
Guillem J, et al. Guidelines 2000 for colon and rectal cancer
surgery. J Natl Cancer Inst 2001; 93: 583-96.
33. Otchy D, Hyman NH, Simmang C, Anthony T, Buie WD,
Cataldo P, et al. Practice parameters for colon cancer. Dis
Colon Rectum 2004; 47: 1269-84.
34. Adam IJ, Mohamdee MO, Martin IG, Scott N, Finan PJ,
Johnston D, et al. Role of circumferential margin involve-
ment in the local recurrence of rectal cancer. Lancet 1994;
344: 707-11.
35. Senagore AJ, Warmuth AJ, Delaney CP, Tekkis PP, Fazio
VW. POSSUM, p-POSSUM, and Cr-POSSUM: imple-
mentation issues in a United States health care system
for prediction of outcome for colon cancer resection. Dis
Colon Rectum 2004; 47: 1435-41.
36. Langevin JM, Nivatvongs S. The true incidence of sync-
hronous cancer of the large bowel. A prospective study.
Am J Surg 1984; 147: 330-3.
37. A comparison of laparoscopically assisted and open
colectomy for colon cancer. N Engl J Med 2004; 350: 2050-9.
38. Fleshman J, Sargent DJ, Green E, Anvari M, Stryker SJ,
Beart RW, Jr., et al. Laparoscopic colectomy for cancer is
not inferior to open surgery based on 5-year data from the
COST Study Group trial. Ann Surg 2007; 246: 655-62; dis-
cussion 662-54.
39. Buunen M, Veldkamp R, Hop WC, Kuhry E, Jeekel J,
Haglind E, et al. Survival after laparoscopic surgery versus
open surgery for colon cancer: long-term outcome of a
randomised clinical trial. Lancet Oncol 2009; 10: 44-52.
40. Veldkamp R, Kuhry E, Hop WC, Jeekel J, Kazemier G,
Bonjer HJ, et al. Laparoscopic surgery versus open surgery
for colon cancer: short-term outcomes of a randomised
trial. Lancet Oncol 2005; 6: 477-84.
41. Guillou PJ, Quirke P, Thorpe H, Walker J, Jayne DG, Smith
AM, et al. Short-term endpoints of conventional versus
laparoscopic-assisted surgery in patients with colorectal
cancer (MRC CLASICC trial): multicentre, randomised
controlled trial. Lancet 2005; 365: 1718-26.
42. Jayne DG, Guillou PJ, Thorpe H, Quirke P, Copeland J,
Smith AM, et al. Randomized trial of laparoscopic-assisted
resection of colorectal carcinoma: 3-year results of the UK
MRC CLASICC Trial Group. J Clin Oncol 2007; 25: 3061-8.
43. Luglio G, Nelson H. Laparoscopy for colon cancer: state of
the art. Surg Oncol Clin N Am 2010; 19: 777-91.
44. Turnbull RB, Jr., Kyle K, Watson FR, Spratt J. Cancer of the
colon: the influence of the no-touch isolation technic on
survival rates. Ann Surg 1967; 166: 420-7.
45. Rouffet F, Hay JM, Vacher B, Fingerhut A, Elhadad A,
Flamant Y, et al. Curative resection for left colonic carc-
inoma: hemicolectomy vs. segmental colectomy. A pro-
spective, controlled, multicenter trial. French Association
for Surgical Research. Dis Colon Rectum 1994; 37: 651-9.
46. Law CH, Wright FC, Rapanos T, Alzahrani M, Hanna
SS, Khalifa M, et al. Impact of lymph node retrieval and
pathological ultra-staging on the prognosis of stage II
colon cancer. J Surg Oncol 2003; 84: 120-6.
47. Whelan RL, Wong WD, Goldberg SM, Rothenberger DA.
Synchronous bowel anastomoses. Dis Colon Rectum 1989;
32: 365-8.
48. Andre T, Boni C, Navarro M, Tabernero J, Hickish T,
Topham C, et al. Improved overall survival with oxalip-
latin, fluorouracil, and leucovorin as adjuvant treatment
in stage II or III colon cancer in the MOSAIC trial. J Clin
Oncol 2009; 27: 3109-16.
49. Benson AB, 3rd, Schrag D, Somerfield MR, Cohen AM,
Figueredo AT, Flynn PJ, et al. American Society of Clinical
Oncology recommendations on adjuvant chemotherapy
for stage II colon cancer. J Clin Oncol 2004; 22: 3408-19.
50. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius
B, Haustermans K, et al. ESMO Consensus Guidelines for
management of patients with colon and rectal cancer. A
personalized approach to clinical decision making. Ann
Oncol 2012; 23: 2479-516.
51. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B,
Nordlinger B, et al. Colorectal cancer. Lancet 2010; 375:
1030-47.
52. Gill S, Loprinzi C, Kennecke H, Grothey A, Nelson G,
Woods R, et al. Prognostic web-based models for stage II
and III colon cancer: A population and clinical trials-based
validation of numeracy and adjuvant! online. Cancer 2011;
117: 4155-65.
53. Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD,
Booth CM. Association between time to initiation of
adjuvant chemotherapy and survival in colorectal cancer:
a systematic review and meta-analysis. JAMA 2011; 305:
2335-42.
54. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M,
Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and
leucovorin as adjuvant treatment for colon cancer. N Engl
J Med 2004; 350: 2343-51.
55. Twelves C, Wong A, Nowacki MP, Abt M, Burris H, 3rd,
Carrato A, et al. Capecitabine as adjuvant treatment for
stage III colon cancer. N Engl J Med 2005; 352: 2696-704.
56. Sanoff HK, Carpenter WR, Sturmer T, Goldberg RM,
Martin CF, Fine JP, et al. Effect of adjuvant chemotherapy
on survival of patients with stage III colon cancer diagno-
sed after age 75 years. J Clin Oncol 2012; 30: 2624-34.
57. Tournigand C, Andre T, Bonnetain F, Chibaudel B, Lledo
G, Hickish T, et al. Adjuvant therapy with fluorouracil and
oxaliplatin in stage II and elderly patients (between ages
70 and 75 years) with colon cancer: subgroup analyses
of the Multicenter International Study of Oxaliplatin,
Fluorouracil, and Leucovorin in the Adjuvant Treatment
of Colon Cancer trial. J Clin Oncol 2012; 30: 3353-60.
58. de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero
J, Clarke S, Moore MJ, et al. Bevacizumab plus oxalip-
latin-based chemotherapy as adjuvant treatment for colon
cancer (AVANT): a phase 3 randomised controlled trial.
Lancet Oncol 2012; 13: 1225-33.
59. Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M,
Thibodeau SN, et al. Effect of oxaliplatin, fluorouracil, and
leucovorin with or without cetuximab on survival among
patients with resected stage III colon cancer: a randomized
trial. JAMA 2012; 307: 1383-93.
60. Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti
JK, Buyse M, et al. Disease-free survival versus overall
survival as a primary end point for adjuvant colon cancer
studies: individual patient data from 20,898 patients on 18
randomized trials. J Clin Oncol 2005; 23: 8664-70.
Heimildir nr 61-114 eru
á heimasíðu Læknablaðsins
Y F i R l i T S G R E i n
Cloxabix (celecoxib) er notað til meðhöndlunar
á einkennum slitgigtar, iktsýki, og hryggiktar
Góður liðstyrkur
til meðferðar við gigt